TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11156123

Group type: EXPERIMENTAL
Intervention: SMA group (surface modifying additives circuit)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study: 9201061

Group type: EXPERIMENTAL
Intervention: PEEP at 5 cm H2O
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: PEEP at 10 cm H2O
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: PEEP at 15 cm H2O
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: PEEP levels (5, 10, 15 cm H2O)
Number of subjects: 18
Study: 1436902

Group type: EXPERIMENTAL
Intervention: Scintigraphy with 99Tcm-HMPAO-labelled platelets
Number of subjects: 33
Study: 3898440

Group type: EXPERIMENTAL
Intervention: Ceftriaxone (1 gram preoperative dose)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Cefazolin (three 1 gram parenteral doses over a 16 hour period)
Number of subjects: 225
Study: 31385425

Group type: EXPERIMENTAL
Intervention: IDegLira
Number of subjects: 506

Group type: COMPARATOR
Intervention: Basal-bolus therapy
Number of subjects: 506
Study: 29852180

Group type: EXPERIMENTAL
Intervention: Decision aid exposure
Number of subjects: 1336

Group type: EXPERIMENTAL
Intervention: Decision aid from the United States Preventive Services Task Force
Number of subjects: 1336
Study: 27670865

Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (MBI)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Standard intervention
Number of subjects: 18
Study: 24641678

Group type: EXPERIMENTAL
Intervention: levodopa 0.76 mg/kg with 25% carbidopa
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: levodopa 0.51 mg/kg with 25% carbidopa
Number of subjects: 45

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 45
Study: 22729015

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 40
Study: 20425703

Group type: EXPERIMENTAL
Intervention: Early atropine protocol (Group 2)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional protocol (Group 1)
Number of subjects: 100
Study: 18823469

Group type: COMPARATOR
Intervention: 30 mg ketorolac i.v. after induction of anaesthesia
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: 120 mg etoricoxib orally as premedication
Number of subjects: 133
Study: 15932662

Group type: EXPERIMENTAL
Intervention: Successful PCI group
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (not receiving PCI or IRA not re‐opened)
Number of subjects: 64
Study: 12460706

Group type: EXPERIMENTAL
Intervention: Losartan (50 mg/day)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Hydrochlorthiazide (12.5 mg/day)
Number of subjects: 11
Study: 10783990

Group type: EXPERIMENTAL
Intervention: Palliative chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Current chemotherapy options
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New developments in chemotherapy
Number of subjects: 0
Study: 8842510

Group type: EXPERIMENTAL
Intervention: Active treatment (transdermal nicotine patches)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 1345755

Group type: EXPERIMENTAL
Intervention: Combination therapy with zidovudine and dideoxycytidine (ddC)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Regimens containing 600 mg of zidovudine daily (regimens 2 and 5)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Lowest zidovudine dose alone (regimen 6)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Addition of ddC to regimen 6 (regimen 3)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Combination therapy with zidovudine and ddC at the doses tested
Number of subjects: 56

Group type: COMPARATOR
Intervention: Daily oral dose of 150 mg of zidovudine
Number of subjects: 56
Study: 6735963

Group type: EXPERIMENTAL
Intervention: Oltipraz administered under fasting conditions (25 mg/kg)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Oltipraz administered with a low fat meal (less than 5% fat)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Oltipraz administered with a high fat meal (24% fat)
Number of subjects: 7
Study: 31115592

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (5 mg intravenous infusion) + calcium + calcitriol
Number of subjects: 40

Group type: COMPARATOR
Intervention: Calcium + calcitriol
Number of subjects: 40
Study: 28011183

Group type: EXPERIMENTAL
Intervention: Mono-cortical plate fixation
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Hybrid fixation
Number of subjects: 76

Group type: COMPARATOR
Intervention: Bi-cortical plate fixation
Number of subjects: 76
Study: 25043261

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical stimulation (ES) at 5 and 50 Hz, with pulse durations of 20, 100, 400, 1000, and 3000 μs.
Number of subjects: 80
Study: 23657766

Group type: EXPERIMENTAL
Intervention: Whole body vibration training (WBV)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Usual-care control (CON)
Number of subjects: 40
Study: 21644105

Group type: EXPERIMENTAL
Intervention: Morphine 0.2 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fentanyl 25 µg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fentanyl 12.5 µg plus Morphine 0.1 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study: 18259794

Group type: EXPERIMENTAL
Intervention: New ultrasonic scissors
Number of subjects: 100

Group type: COMPARATOR
Intervention: Resterilized ultrasonic scissors
Number of subjects: 100
Study: 16491208

Group type: EXPERIMENTAL
Intervention: Fixed combination of amlodipine and losartan
Number of subjects: 198

Group type: COMPARATOR
Intervention: Amlodipine alone
Number of subjects: 198

Group type: COMPARATOR
Intervention: Losartan alone
Number of subjects: 198
Study: 12794792

Group type: EXPERIMENTAL
Intervention: Intravenous doxycycline
Number of subjects: 30
Study: 11551003

Group type: EXPERIMENTAL
Intervention: 1-year hospital-based secondary prevention programme (SPP)
Number of subjects: 241

Group type: COMPARATOR
Intervention: Conventional care (CC)
Number of subjects: 241
Study: 9242857

Group type: EXPERIMENTAL
Intervention: Original instructions
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Revised instructions
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Second revised instructions
Number of subjects: 60
Study: 8486017

Group type: EXPERIMENTAL
Intervention: Unsupported arm exercise (UAEx)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Supported arm exercise (SAEx)
Number of subjects: 40
Study: 3129362

Group type: EXPERIMENTAL
Intervention: rIFN-gamma (0.01 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: rIFN-gamma (0.1 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: rIFN-gamma (0.5 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: rIFN-gamma (all doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: rIFN-gamma (highest dose level)
Number of subjects: 0
Study: 2806493

Group type: EXPERIMENTAL
Intervention: terbutaline
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: tobacco exposure
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: combination of smoking and terbutaline
Number of subjects: 9

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 9
Study: 31523780

Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MedDiet) adherence improvement
Number of subjects: 5777
Study: 29449791

Group type: EXPERIMENTAL
Intervention: Caffeine (CAF) 200 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (PLA) 200 mg dextrose
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (CON) no supplementation
Number of subjects: 20
Study: 27723543

Group type: EXPERIMENTAL
Intervention: Low-dose curcumin extract (250mg b.i.d.)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: High-dose curcumin extract (500mg b.i.d.)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Combined low-dose curcumin extract plus saffron (15mg b.i.d.)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Active drug treatments (combined)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study: 25262675

Group type: EXPERIMENTAL
Intervention: Erythritol air-polishing powder (EPAP)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Scaling and root planing (SRP)
Number of subjects: 40
Study: 23199378

Group type: EXPERIMENTAL
Intervention: rhBMP-2 treatment
Number of subjects: 508

Group type: COMPARATOR
Intervention: Control group (autograft or lumbar disc treatment)
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: Surgical approach (retroperitoneal)
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: Surgical approach (transperitoneal)
Number of subjects: 508
Study: 21499725

Group type: EXPERIMENTAL
Intervention: Lysine hyaluronate (Lys-HA)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sodium hyaluronate (SH)
Number of subjects: 50
Study: 18450417

Group type: EXPERIMENTAL
Intervention: Frontal Systems Behavioral Scale (FrSBe) for F-ABI patients
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Frontal Systems Behavioral Scale (FrSBe) for substance abusers
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Frontal Systems Behavioral Scale (FrSBe) total score for F-ABI patients
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Frontal Systems Behavioral Scale (FrSBe) total score for substance abusers
Number of subjects: 139

Group type: COMPARATOR
Intervention: Frontal Systems Behavioral Scale (FrSBe) total score for controls
Number of subjects: 139
Study: 16506027

Group type: COMPARATOR
Intervention: autologous iliac graft (n=6)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: autologous iliac graft + osteogenic protein-1 (OP-1; n=6)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: allogenic iliac graft + OP-1 (n=5)
Number of subjects: 17
Study: 15531489

Group type: EXPERIMENTAL
Intervention: r-metHuLeptin (0.05 mg/kg sc daily)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 11579010

Group type: EXPERIMENTAL
Intervention: Tandospirone (30 mg/day)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 9217971

Group type: EXPERIMENTAL
Intervention: Fas ligand (FasL) expression in glioblastoma cell lines and primary astrocytic brain tumors
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Immunohistochemical assessment of FasL
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Induction of Fas expression
Number of subjects: 24
Study: 7968119

Group type: EXPERIMENTAL
Intervention: Amoxycillin (500 mg three times daily for 7 days)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Erythromycin (500 mg four times daily for 7 days)
Number of subjects: 210
Study: 3475663

Group type: EXPERIMENTAL
Intervention: Local anesthetic blocking of the auriculotemporal nerve
Number of subjects: 208

Group type: COMPARATOR
Intervention: Placebo injections of saline solution
Number of subjects: 208
Study: 29224730

Group type: EXPERIMENTAL
Intervention: Induction of labor with an unfavorable cervix (Bishop score ≤6 and dilation ≤2 cm)
Number of subjects: 8466

Group type: EXPERIMENTAL
Intervention: Nomogram and Web-based calculator for predicting cesarean delivery
Number of subjects: 8466
Study: 26163860

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT)
Number of subjects: 21
Study: 24962851

Group type: EXPERIMENTAL
Intervention: Oral nitric oxide supplement (lozenge)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 22343481

Group type: EXPERIMENTAL
Intervention: Kripalu-based yoga program (2 to 3 times a week for 10 weeks)
Number of subjects: 51

Group type: COMPARATOR
Intervention: PE-as-usual (control group)
Number of subjects: 51
Study: 20524068

Group type: EXPERIMENTAL
Intervention: MedCoat coated placebo tablets
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: MedCoat coated divided non-flavoured placebo tablets
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: MedCoat coated bitter flavoured placebo tablets
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: MedCoat
Number of subjects: 41
Study: 18955426

Group type: EXPERIMENTAL
Intervention: Structured educational programme of daily incremental physical activity at home (walking and skeletal muscle resistance training, with booklets and written instructions)
Number of subjects: 52

Group type: COMPARATOR
Intervention: General advice regarding exercise and long-term fitness (control group)
Number of subjects: 52
Study: 16164766

Group type: EXPERIMENTAL
Intervention: Brief eclectic psychotherapy for 4 months (n=9)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Waiting-list group (n=9)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: PTSD patients (n=18)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Traumatized control subjects (n=14)
Number of subjects: 18
Study: 14753103

Group type: EXPERIMENTAL
Intervention: Test group 1 (10 teeth): Acid-etched and sealed enamel area with surrounding sound enamel subjected to demineralization.
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Test group 2 (13 teeth): Demineralized enamel window that was subsequently etched and sealed.
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (5 teeth): Baseline reference for test procedures.
Number of subjects: 28
Study: 11524323

Group type: EXPERIMENTAL
Intervention: EMLA cream and inhaled air and oxygen
Number of subjects: 40

Group type: COMPARATOR
Intervention: Nitrous oxide (N2O) with placebo cream and inhaled 70% N2O in oxygen
Number of subjects: 40

Group type: COMPARATOR
Intervention: N2O
Number of subjects: 40
Study: 9236570

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy in hospitals with higher perioperative mortality rates than trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy in patients with comorbidity exceeding trial criteria
Number of subjects: 0
Study: 8515137

Group type: EXPERIMENTAL
Intervention: Once-weekly external microwave hyperthermia treatments combined with radiation therapy
Number of subjects: 41

Group type: COMPARATOR
Intervention: Twice-weekly external microwave hyperthermia treatments combined with radiation therapy
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Once-weekly hyperthermia
Number of subjects: 41

Group type: COMPARATOR
Intervention: Twice-weekly hyperthermia
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 41
Study: 3822503

Group type: EXPERIMENTAL
Intervention: Low osmolar (LO) compound
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: High osmolar (HO) compound
Number of subjects: 162

Group type: COMPARATOR
Intervention: 0.9% NaCl (placebo) (PL)
Number of subjects: 162
Study: 31980143

Group type: EXPERIMENTAL
Intervention: Adjuvant capecitabine for six months at the usual dose
Number of subjects: 450

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 450
Study: 31586838

Group type: EXPERIMENTAL
Intervention: Repeated ketamine-assisted ECT (group RK), ketamine at the dose of 0.3 mg/kg for each ECT treatment
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Intermittent ketamine-assisted ECT (group IK), ketamine once a week during ECT course
Number of subjects: 134

Group type: COMPARATOR
Intervention: Routine ECT group (group E)
Number of subjects: 134
Study: 26973025

Group type: EXPERIMENTAL
Intervention: Intravenous progesterone
Number of subjects: 575

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 575
Study: 25966929

Group type: EXPERIMENTAL
Intervention: APC8015-2 (an investigational form of sipuleucel-T)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Commercial sipuleucel-T
Number of subjects: 1
Study: 24072967

Group type: EXPERIMENTAL
Intervention: Resistance training (n = 10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (n = 10)
Number of subjects: 20
Study: 21127896

Group type: EXPERIMENTAL
Intervention: Cooling vest with PCM at 24°C melting temperature
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Cooling vest with PCM at 28°C melting temperature
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control group without vest
Number of subjects: 3
Study: 19577876

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DMED)
Number of subjects: 3
Study: 17952277

Group type: EXPERIMENTAL
Intervention: Posterior lumbar spinal fusion with pedicle screws (PLF)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Posterior lumbar interbody fusion with pedicle screws (PLIF)
Number of subjects: 60
Study: 15292035

Group type: EXPERIMENTAL
Intervention: Glucose ingestion
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (no glucose ingestion)
Number of subjects: 20
Study: 11720830

Group type: EXPERIMENTAL
Intervention: Oral clodronate 1600 mg daily for 3 years
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 73
Study: 9740462

Group type: EXPERIMENTAL
Intervention: Combination of 600 mg oral mifepristone and 50 mg/m2 methotrexate
Number of subjects: 50

Group type: COMPARATOR
Intervention: 50 mg/m2 methotrexate alone
Number of subjects: 50
Study: 7810153

Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 24
Study: 3380557

Group type: EXPERIMENTAL
Intervention: Stellate ganglion blockade with bupivacaine
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Intravenous regional sympathetic blockade with guanethidine
Number of subjects: 28

Group type: COMPARATOR
Intervention: Sham (placebo) injection with physiologic saline
Number of subjects: 28

Group type: COMPARATOR
Intervention: Bupivacaine intramuscularly
Number of subjects: 28
Study: 30008242

Group type: EXPERIMENTAL
Intervention: Tai Chi Chuan (TCC)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Brisk Walking (BW)
Number of subjects: 48
Study: 27564555

Group type: EXPERIMENTAL
Intervention: Ramosetron 0.3 mg
Number of subjects: 296

Group type: COMPARATOR
Intervention: Palonosetron 0.075 mg
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Ramosetron 0.3 mg (TT genotype patients)
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Ramosetron 0.3 mg (non-TT genotype patients)
Number of subjects: 296

Group type: COMPARATOR
Intervention: Palonosetron 0.075 mg (TT genotype patients)
Number of subjects: 296
Study: 25286965

Group type: EXPERIMENTAL
Intervention: 1% lidocaine mixed with dexamethasone 2.5 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 0.125% lidocaine mixed with dexamethasone 2.5 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Both groups (1% lidocaine and 0.125% lidocaine)
Number of subjects: 30
Study: 23154578

Group type: EXPERIMENTAL
Intervention: 20 mg/d lutein (A+L)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo (A+P)
Number of subjects: 65
Study: 21632713

Group type: EXPERIMENTAL
Intervention: Sleep after vaccination
Number of subjects: 27

Group type: COMPARATOR
Intervention: Wakefulness after vaccination
Number of subjects: 27
Study: 19493418

Group type: EXPERIMENTAL
Intervention: Group S1 (propofol target plasma concentration of 4.0 microg/ml)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Group S2 (initial target plasma concentration of 2.0 microg/ml raised to 4.0 microg/ml after 3 minutes)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Group S3 (three-step TCI starting from 2.0 microg/ml to 4.0 microg/ml)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Group S1
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: All groups after intubation
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Correlation analysis
Number of subjects: 90
Study: 16686565

Group type: EXPERIMENTAL
Intervention: Step aerobics training (50 minutes per day, 3 days per week for 10 weeks, at 60-80% of heart rate reserve)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Step aerobics training
Number of subjects: 118
Study: 15225166

Group type: EXPERIMENTAL
Intervention: Interferon alpha-2b (5 million units daily for 2 months)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (historical series of 16 untreated patients)
Number of subjects: 28
Study: 11426093

Group type: EXPERIMENTAL
Intervention: 5g intravenous bolus of MgSO4
Number of subjects: 14

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 14
Study: 9231547

Group type: COMPARATOR
Intervention: Regular heparin (Group I) in conventional dose as continuous infusion for 5 days
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Fixed-dose low molecular weight heparin (LMWH) (Group II), 3500 units subcutaneous twice daily for a period of 5 days
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups (Group I and Group II)
Number of subjects: 40
Study: 7589598

Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg given twice daily with chemotherapy
Number of subjects: 35

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 35
Study: 2141109

Group type: EXPERIMENTAL
Intervention: L-carnitine (3 g orally daily)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 114198

Group type: EXPERIMENTAL
Intervention: 21-day regimen of triple tetracycline (Deteclo), one tablet twice daily for 21 days
Number of subjects: 143

Group type: COMPARATOR
Intervention: 7-day regimen of triple tetracycline (Deteclo), one tablet twice daily for 7 days
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: 21-day regimen of triple tetracycline (Deteclo)
Number of subjects: 143

Group type: COMPARATOR
Intervention: 7-day regimen of triple tetracycline (Deteclo)
Number of subjects: 143
Study: 30975950

Group type: EXPERIMENTAL
Intervention: Transversus abdominis plane (TAP) block
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study: 27988967

Group type: EXPERIMENTAL
Intervention: Brivaracetam (BRV) 50 mg/day
Number of subjects: 1160

Group type: EXPERIMENTAL
Intervention: Brivaracetam (BRV) 100 mg/day
Number of subjects: 1160

Group type: EXPERIMENTAL
Intervention: Brivaracetam (BRV) 200 mg/day
Number of subjects: 1160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1160
Study: 25777347

Group type: EXPERIMENTAL
Intervention: Disulfiram (40 mg three times daily)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Chemotherapy (cisplatin and vinorelbine) without disulfiram
Number of subjects: 40
Study: 24884848

Group type: EXPERIMENTAL
Intervention: Immediate loading of a single mandibular midline implant with an overdenture
Number of subjects: 180

Group type: COMPARATOR
Intervention: Delayed loading of a single mandibular midline implant with an overdenture
Number of subjects: 180
Study: 21735533

Group type: EXPERIMENTAL
Intervention: Thrombus aspiration (TA) during primary percutaneous coronary intervention (PPCI)
Number of subjects: 619

Group type: COMPARATOR
Intervention: Conventional PPCI without thrombus aspiration
Number of subjects: 619